Recent Updates
Recently added Catalysts
GILD Positive Sentiment Score: 85/100

CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

Friday, July 24, 2026 1 min read
Key Takeaway: Gilead Sciences has received a positive recommendation from the CHMP for Trodelvy in combination with Keytruda for treating adult patients with unresectable locally advanced or metastatic triple-negative breast cancer. This marks a significant step towards marketing authorization in the EU, enhancing treatment options for patients who have not yet received therapy.

Market Sentiment Analysis

POSITIVE FACTORS

  • CHMP's positive opinion for Trodelvy and Keytruda combination.
  • Potential to treat metastatic triple-negative breast cancer effectively.
  • Gilead's advancement in oncology with innovative therapies.

Full Press Release Details

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab), for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received

Frequently Asked Questions

What is Trodelvy used for?

Trodelvy is used for treating adult patients with metastatic triple-negative breast cancer.

What does CHMP's recommendation mean?

CHMP's recommendation indicates a positive opinion for marketing authorization in the EU.

Who are the patients for this treatment?

The treatment is for adults with unresectable locally advanced or metastatic TNBC.

What is the significance of this recommendation?

It enhances treatment options for patients who have not received prior therapy.

Tags: GILD Viatris Investor Conferences Healthcare Gilead Trodelvy Keytruda TNBC EMA
Last updated: Jul 24, 2026

Biotech snapshot

Cash runway
$7628M liquidity · $0M/mo burn
Low dilution risk
Lead asset
RanolazinePhase 3
Myocardial Ischemia →

Catalyst track record

+15%
best trade around GILD's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for GILD.

See every catalyst's timing & PoA →